Search Results for: CYB5B

58 interactions involving CYB5B - cytochrome b5 type B found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
Novel B3GNT9 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9
  • O-linked glycosylation of mucins
Novel CENPT centromere protein T
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
Novel COG8 component of oligomeric golgi complex 8
  • COPI-mediated anterograde transport
  • Intra-Golgi traffic
  • Retrograde transport at the Trans-Golgi-Network
  • Congenital disorders of glycosylation (CDG) type II
Novel ESRP2 epithelial splicing regulatory protein 2
  • FGFR2 alternative splicing
Novel PHAF1 phagophore assembly factor 1
Novel RPS2P45 ribosomal protein S2 pseudogene 45
Novel SLC7A6OS solute carrier family 7 member 6 opposite strand
AHNAK2 AHNAK nucleoprotein 2
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1-dependent IKK and NF-kappa-B activation
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Gantenerumab
  • Aducanumab
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Lecanemab
  • Alzheimer's disease (AD)
AQP6 aquaporin 6
  • Passive transport by Aquaporins
BIK BCL2 interacting killer
BNIP3L BCL2 interacting protein 3 like
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
BTNL9 butyrophilin like 9
  • Butyrophilin (BTN) family interactions
CD33 CD33 molecule
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Neutrophil degranulation
  • Gemtuzumab ozogamicin
  • AVE9633
CD79A CD79a molecule
  • CD22 mediated BCR regulation
  • Potential therapeutics for SARS
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
CGRRF1 cell growth regulator with ring finger domain 1
CLDN7 claudin 7
  • Tight junction interactions
CLN8 CLN8 transmembrane ER and ERGIC protein
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
CPLX4 complexin 4
CREB3 cAMP responsive element binding protein 3
  • CREB3 factors activate genes
  • CREB3 factors activate genes

Page 1 out of 3 pages